Literature DB >> 2265794

Vancomycin in resistant hepatic encephalopathy.

A Forbes, I Murray-Lyon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2265794      PMCID： PMC1378785          DOI： 10.1136/gut.31.12.1424-b

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  7 in total

1.  Absorption of orally administered neomycin and kanamycin with special reference to patients with severe hepatic and renal disease.

Authors:  C M KUNIN; T C CHALMERS; C M LEEVY; S C SEBASTYEN; C S LIEBER; M FINLAND
Journal:  N Engl J Med       Date:  1960-02-25       Impact factor: 91.245

Review 2.  Progress in the treatment of chronic portasystemic encephalopathy.

Authors:  I R Crossley; R Williams
Journal:  Gut       Date:  1984-01       Impact factor: 23.059

3.  Audiotoxicity and nephrotoxicity due to orally administered neomycin.

Authors:  L H Greenberg; H Momary
Journal:  JAMA       Date:  1965-11-15       Impact factor: 56.272

Review 4.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

5.  Absorption of oral vancomycin - possible associated toxicity.

Authors:  C M Thompson; S S Long; P H Gilligan; J W Prebis
Journal:  Int J Pediatr Nephrol       Date:  1983-03

6.  Ototoxicity of oral neomycin and vancomycin.

Authors:  K T Kavanagh; B F McCabe
Journal:  Laryngoscope       Date:  1983-05       Impact factor: 3.325

7.  Systemic absorption of oral vancomycin in patients with renal insufficiency and antibiotic-associated colitis.

Authors:  G R Matzke; C E Halstenson; P L Olson; A J Collins; P A Abraham
Journal:  Am J Kidney Dis       Date:  1987-05       Impact factor: 8.860
  7 in total
  1 in total

1.  Managing complications in cirrhotic patients.

Authors:  Markus Peck-Radosavljevic; Paolo Angeli; Juan Cordoba; Oliver Farges; Dominique Valla
Journal:  United European Gastroenterol J       Date:  2015-02       Impact factor: 4.623
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.